
CLAIMS

1. Ophthalmologic preparation containing hyaluronic acid, **characterized in that,** it is in a form of a solid fibrous carrier that comprises water soluble nano-fibers containing hyaluronic acid or a pharmaceutically acceptable salt thereof,

and/or at least one derivative of hyaluronic acid of a general formula I



(I),

wherein R^+ is H^+ or pharmaceutically acceptable salt,

R^1 is H or $–C(=O)C_xH_y$ or furanyl, where x is integer in the range 3 to 21 and y is integer in the range 7 to 43 and C_xH_y is linear or branched, saturated or unsaturated chain C_3-C_{21}, one or more R^1-$C(=O)C_xH_y$ or furanyl being at least in one repeating unit and where n is in the range 12 to 4 000,

and at least one a water soluble synthetic polymer selected from the group containing polyethylene oxide or polyvinyl alcohol,

and at least one active agent is contained in the whole capacity of nano-fibers.

2. Ophthalmologic preparation according to claim 1, **characterized in that,** the derivative of hyaluronic acid is selected from the group containing palmitoyl hyaluronan, caproyl hyaluronan, oleyl hyaluronan, butanoyl hyaluronan, linoleoyl hyaluronan or furanyl hyaluronan.

3. Ophthalmologic preparation according to claim 1 or 2, **characterized in that,** the active agent is selected from the group containing anti-allergic, antibiotic, antimycotic, antineoplastic, anti-inflammatory, antiviral, antiglaucoma, antiseptic or diagnostic agent.

4. Ophthalmologic preparation according to claim 3, **characterized in that,** the active agent is hydrophobic, and it is contained in the nano-fibers in the form of micelles.

5. Ophthalmologic preparation according to claims 3 or 4, **characterized in that,** the content of the active agent is 0.01 to 50 wt.%, preferably 0.1 to 50 wt.%.

6. Ophthalmologic preparation according to any one of claims 1 to 5, **characterized in that**, the content of hyaluronic acid and/or derivative of hyaluronic acid or pharmaceutically acceptable salts thereof is in the range 5 to 90 wt.%, preferably 10 to 90 wt.%, more preferably 50 to 80 wt.%.

7. Ophthalmologic preparation according to claim 6, **characterized in that,** the mass ratio of hyaluronic acid or salt thereof and derivative of hyaluronic acid is 1/9 to 9/1, preferably 3/7 to 7/3.

8. Ophthalmologic preparation according to any one of the claims 1 to 7, **characterized in that,** the content of the synthetic polymer or the mixture thereof is in the range 10 to 95 wt.%, preferably 10 to 90 wt.%, more preferably 20 to 50 wt.%.

9. Ophthalmologic preparation according to the claim 8, **characterized in that,** the mass ratio of polyethylene oxide and polyvinyl alcohol in the mixture is in the range 19/1 to 3/17.

10. Ophthalmologic preparation according to any one of the claims 1 to 9, **characterized in that,** the nano-fibers have diameters in the range 50 to 1 000 nm, preferably 50 to 500 nm, more preferably 50 to 200 nm.

11. Ophthalmologic preparation according to any one of the claims 1 to 10, **characterized in that**, it is in the form of the nano-fibrous layer, the areal mass thereof being in the range 1 to 100 g/m^2, preferably in the range from 1 to 20 g/m^2, more preferably from 3 to 17 g/m^2.

12. A holder comprising the ophthalmologic preparation according to any one of the claims 1 to 11 for manipulation during the application of the ophthalmologic preparation.

13. Use of an ophthalmologic preparation according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment or prevention of ophthalmologic diseases and disorders selected from a group comprising glaucoma, syndrome of dry eye, macular degeneration, infection, inflammation or allergy.